Diligence memo · auto-generated · as of July 2, 2026
Porosome Therapeutics, Inc.
Porosome Therapeutics, Inc. looks over-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Porosome Therapeutics, Inc. operates in Biotechnology, based in BOSTON.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Porosome Therapeutics, Inc. has raised $3.9M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $3.6M on 2023-09-08.
Most recent recorded round closed around 2023-09-08.
Valuation (modeled)modeled
Provath models Porosome Therapeutics, Inc. at approximately $28M (range $2.6M–$91M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.94× the median modeled value of Seed Biotechnology companies in 2022–2024 (207 peers) — value vs value, same stage and era. Issuer reports no revenue, yet is modeled well above niche peers.
Financing rhythm & timingmixed
Historic cadence: a new round about every 4 months.
Last raise 2.8 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 2.4× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 39% of Biotechnology peers (4293 compared).
Modeled value ranks above 33% of those peers.
Closest niche peers: Mesentech Inc., Marlinspike Therapeutics, Inc., Microbial Machines, Inc., Pearl Diagnostics, Inc., Crossfire Medical Inc.
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.